A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT03104374
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGOral tablet
- Upadacitinib — DRUGOral tablet
Study Details
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who had an inadequate response to Biological Disease Modifying Anti-Rheumatic Drug (bDMARDs). Period 2 evaluated the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who completed Period 1.
Key Dates
- Start date
- May 1, 2017
- Status verified
- Aug 2025
- Primary completion
- Jul 23, 2019
- Completion
- Sep 30, 2024
Study Design
- Enrollment
- 642 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Upadacitinib 15 mgAdministered once daily.
- Placebo Comparator: Placebo / Upadacitinib 30 mgAdministered once daily.
- Experimental: Upadacitinib 30 mgAdministered once daily.
- Placebo Comparator: Placebo / Upadacitinib 15 mgAdministered once daily.
Primary Outcome Measure
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 [ Time Frame: Baseline and Week 12 ]
Locations (72)
Find similar trials in Mobile, AL
By condition
By research site
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Stronger Together Psoriatic Arthritis Wellness StudyRecruiting · Global Healthy Living Foundation · Upper Nyack, New York